Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Total Current Liabilities
All obligations due within one year.
Aktis Oncology, Inc.NASDAQ: AKTS
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities of $27.91M in Q1 FY2026
Q1 FY2026 total current liabilities was $27.91M. Over 3 fiscal years it compounded at +80.9% a year.
Context
- Total current liabilities amounted to 4.8% of total assets at the end of Q1 FY2026.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 31.24M USD
- Year-over-year change
- +66.0%
- 3-year CAGR
- +80.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.24M | +66.0% |
| FY2024 | 2024-12-31 | 18.82M | +201.8% |
| FY2023 | 2023-12-31 | 6.24M | +18.2% |
| FY2022 | 2022-12-31 | 5.28M | — |
Total Current Liabilities vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 total current liabilities of $27.91M is the 5th highest of the 6 companies compared; the peer median is $48.89M.
- Total current liabilities amounts to 4.8% of total assets for AKTS, versus a peer median of 12.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $240.11M | +61.0% | +34.7% | 22.4% | |
| Mar 2026 | $95.94M | +73.0% | -3.9% | 44.0% | |
| Mar 2026 | $48.89M | -15.2% | +2.2% | 7.5% | |
| Sep 2026 | $40.97M | +30.3% | +83.1% | 8.1% | |
| Mar 2026 | $27.91M | — | +80.9% | 4.8% | |
| Mar 2026 | $16.71M | +37.4% | +20.7% | 12.1% | |
| Peer median (excluding AKTS) | $48.89M | +37.4% | +20.7% | 12.1% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.